


### Exclusion from Outpatient therapeutics

- Patient hospitalized for COVID-19
- OR
- Require oxygen support or increased in baseline home oxygen due to COVID-19

**Patients  $\geq 12$  years old AND weight  $\geq 40$  Kg with mild to moderate COVID-19 infection (confirmed positive SARS-CoV2 test) AND high or moderate risk for progression to severe disease**



### BOX 1 Risk for severe COVID-19

#### High Risk

- Overweight/Obesity ( $\geq 18$  yrs: BMI  $> 25$  kg/m<sup>2</sup>, 12 to 17 yrs: BMI  $\geq 85$ th percentile for their age and gender)
- Severe immunocompromise<sup>1</sup>
- Medical complexity with respiratory technology dependence

#### Moderate Risk

- Mild to moderate immunocompromise<sup>2</sup>
- Chronic respiratory conditions (e.g. patient with asthma on daily controller medicine)
- Congenital heart disease
- Sickle cell disease

#### Low Risk

- Diabetes
- Chronic kidney disease

<sup>1</sup>Examples include patient receiving high-intensity chemotherapy for newly diagnosed or relapsed leukemia, profound antibody deficiency or low lymphocyte count ( $< 100$  cells/ $\mu$ l), CART T-cell therapy, Primary immunodeficiency, hematopoietic cell transplant

<sup>2</sup>Examples include leukemia in remission, solid tumors not receiving intensive chemotherapy, solid organ transplant recipients not on severe immunosuppressive regimen (e.g. lymphocyte depleting therapy)

### Paxlovid Prescribing Checklist

- Follow EUA prescriber requirement (see BOX 2)
- Check patient's medications for drug interactions with Paxlovid (refer to page 2 for additional resources)
- Patient with renal impairment may need dose reduction (see page 2 for details)
- Find a local pharmacy that carries Paxlovid by using the COVID-19 therapeutic locator website ([click here](#))
- Order Paxlovid in EPIC, ensuring prescription is being sent to the correct pharmacy

### BOX 2

#### Prescriber Requirement When Prescribing Therapeutic Under the EUA

##### Prescriber must complete the following:

- Provide the patient/caregiver EUA fact sheet
- Inform of any alternative therapies
- Inform that the prescribed therapeutic is an unapproved drug that is authorized under the EUA

**Note: Paxlovid and bebtelovimab are both EUA**

[Paxlovid Healthcare Provider Factsheet](#)

[Paxlovid Patient/family Factsheet \(English\)](#)

[Paxlovid Patient/family Factsheet \(Spanish\)](#)

[Bebtelovimab Healthcare Provider Factsheet](#)

[Bebtelovimab Patient/family Factsheet \(English\)](#)

[Bebtelovimab Patient/family Factsheet \(Spanish\)](#)

Reference: Joshua Wolf,1, Mark J. Abzug,2 Brenda I. Anosike et al. Updated Guidance on Use and Prioritization of Monoclonal Antibody Therapy for Treatment of COVID-19 in Adolescent. J Ped Infect Dis. Published online Feb 2, 2022

#### For General Questions on Outpatient COVID-19 Therapeutics:

- Please email [COVID19OutptTherapy@Nemours.org](mailto:COVID19OutptTherapy@Nemours.org)
- Messages will be responded to by the next business day

## Agents Approved and Under Emergency Use Authorization (EUA) for Outpatient Management of COVID-19

COVID-19 Treatment	Dose/duration	Comments
<b>Antiviral</b>		
<p><b>Paxlovid (nirmatrelvir tablet and ritonavir tablet)</b></p> <ul style="list-style-type: none"> <li>EUA authorized for <math>\geq 12</math> yrs AND <math>\geq 40</math> kg</li> <li>Active in vitro against all Omicron subvariants</li> <li>Paxlovid consists of two individual medications: nirmatrelvir tablet and ritonavir tablet which are co-packaged to be administered together</li> <li>Nirmatrelvir is active against SARS-CoV-2 virus and ritonavir is a strong cytochrome P450 (CYP) 3A4 inhibitor that serves as a pharmacokinetic boosting agent. Ritonavir is required to increase nirmatrelvir concentrations to the target therapeutic ranges.</li> </ul> <div style="border: 1px solid black; padding: 5px; margin-top: 10px;"> <p><b>COVID-19 Therapeutic Locator</b> Click <a href="#">here</a> to locate a <a href="#">local pharmacy</a> that carries Paxlovid</p> </div>	<p>Nirmatrelvir must be co-administered with ritonavir</p> <p><b><math>\geq 18</math> years or <math>\geq 12</math> years and weighing at least 40kg:</b></p> <ul style="list-style-type: none"> <li>Nirmatrelvir 300 mg with 100 mg ritonavir twice daily for 5</li> </ul> <p><b>Dosing for Impaired renal function</b></p> <ul style="list-style-type: none"> <li>eGFR <math>\geq 60</math> mL/min: no dose adjustment necessary</li> <li>eGFR <math>\geq 30</math> to <math>&lt; 60</math> mL/min: Nirmatrelvir 150 mg with ritonavir 100 mg PO twice daily for 5 days</li> <li>eGFR <math>&lt; 30</math> mL/min: Not recommended</li> </ul>	<ul style="list-style-type: none"> <li>Most common adverse events: dysgeusia, diarrhea, hypertension, and myalgia</li> <li>Has significant drug-drug interactions due to the ritonavir component</li> <li>Before prescribing ritonavir-boosted nirmatrelvir, providers <b>should carefully review the patient's concomitant medications</b>, including over-the-counter medicines and herbal supplements</li> </ul> <div style="border: 1px solid black; padding: 5px; margin-top: 10px;"> <p><b>Resource for Drug-Drug Interaction Check:</b></p> <ul style="list-style-type: none"> <li>Click <a href="#">here</a> for <a href="#">Liverpool COVID-19 Drug Interaction Checker</a> (note: enter nirmatrelvir/ritonavir when searching)</li> <li>Lexicomp Drug Interaction Resource (refer to NCH-D online formulary)</li> </ul> </div> <ul style="list-style-type: none"> <li>Needs dosage adjustment for patients with impaired renal function</li> </ul>
<b>Monoclonal Antibody</b>		
<p><b>Bebtelovimab</b></p> <ul style="list-style-type: none"> <li>EUA authorized for <math>\geq 12</math> yrs AND <math>\geq 40</math> kg</li> <li>Active in vitro against all circulating Omicron subvariants</li> <li>Lacks clinical efficacy data from placebo-controlled trials that evaluated the use of bebtelovimab in patients who are at high risk of progressing to severe COVID-19 (reserved as alternative therapy)</li> </ul> <div style="border: 1px solid black; padding: 5px; margin-top: 10px;"> <p>Call <b>302-298-8750</b> to initiate the referral process for monoclonal antibody infusion</p> </div>	<p><b><math>\geq 18</math> years or <math>\geq 12</math> years and weighing at least 40kg</b></p> <ul style="list-style-type: none"> <li>175 mg administered as a single intravenous injection over at least 30 seconds</li> </ul>	<ul style="list-style-type: none"> <li>Most common adverse reactions are infusion-related reactions (0.3%), pruritus (0.3%), and rash (0.8%).</li> <li>Hypersensitivity Including anaphylaxis and infusion-related reactions anaphylaxis have been observed with administration of other SARS-CoV-2 monoclonal antibodies and could occur with administration of bebtelovimab</li> <li>Monitor patients for possible infusion-related reactions for at least 1 hour after injection is complete</li> </ul>

**Authors:** Craig Shapiro<sup>1,2</sup>, Shannon Chan<sup>1,3</sup>

<sup>1</sup>The Antimicrobial Stewardship Program, <sup>2</sup>Infectious Disease Division, <sup>3</sup>Pharmacy Department

**References:**

- COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at <https://www.covid19treatmentguidelines.nih.gov/>. Accessed [May 18, 2022].
- IDSA Guidelines on the Treatment and Management of Patients with COVID-19. Available at <https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/>. Last updated 5/10/2022

## Other Drugs with Significant Drug interaction with Paxlovid

### Interaction Codes:

XXX

Coadministration of this drug with PAXLOVID is CONTRAINDICATED. For further information, refer to the Fact Sheet for Healthcare Providers and the individual Prescribing Information for the drug.

\*\*\*

Coadministration of this drug with PAXLOVID should be avoided and/or holding of this drug, dose adjustment of this drug, or special monitoring is necessary. Consultation with the prescriber of the potentially interacting drug is recommended. For further information, refer to the Health Care Provider Fact Sheet and the individual Prescribing Information for the drug.

Drug	Drug Class	Interaction Code
abemaciclib	Anticancer drug	***
alfuzosin	Alpha 1-adrenoreceptor antagonist	XXX
amiodarone	Antiarrhythmic	XXX
amlodipine	Calcium channel blocker	***
apalutamide	Anticancer drug	XXX
bedaquiline	Antimycobacterial	***
bepidil	Antiarrhythmic	***
betamethasone	Systemic corticosteroid	***
bosentan	Endothelin receptor antagonist	***
budesonide	Systemic corticosteroid	***
bupropion	Antidepressant	***
carbamazepine	Anticonvulsant	XXX
ceritinib	Anticancer drug	***
ciclesonide	Systemic corticosteroid	***
clarithromycin	Anti-infective	***
clozapine	Antipsychotic	XXX
colchicine	Anti-gout	XXX
cyclosporine	Immunosuppressant	***
dabigatran	Anticoagulants	***
dasabuvir	Hepatitis C direct acting antiviral	***
dasatinib	Anticancer drug	***
dexamethasone	Systemic corticosteroid	***

Drug	Drug Class	Interaction Code
digoxin	Cardiac glycoside	***
dihydroergotamine	Ergot derivative	XXX
diltiazem	Calcium channel blocker	***
dronedarone	Antiarrhythmic	XXX
elbasvir/grazoprevir	Hepatitis C direct acting antiviral	***
encorafenib	Anticancer drug	***
ergotamine	Ergot derivative	XXX
erythromycin	Anti-infective	***
felodipine	Calcium channel blocker	***
fentanyl	Narcotic analgesic	***
flecainide	Antiarrhythmic	XXX
fluticasone	Systemic corticosteroid	***
glecaprevir/pibrentasvir	Hepatitis C direct acting antiviral	***
ibrutinib	Anticancer drug	***
isavuconazonium sulfate	Antifungal	***
itraconazole	Antifungal	***
ivosidenib	Anticancer drug	***
ketoconazole	Antifungal	***
lidocaine (systemic)	Antiarrhythmic	***
lurasidone	Antipsychotic	XXX
methadone	Narcotic analgesic	***
methylergonovine	Ergot derivative	XXX
methylprednisolone	Systemic corticosteroid	***
midazolam (administered parentally)	Sedative/hypnotic	***
midazolam (oral)	Sedative/hypnotic	XXX
mometasone	Systemic corticosteroid	***
neratinib	Anticancer drug	***
nicardipine	Calcium channel blocker	***
nifedipine	Calcium channel blocker	***
nilotinib	Anticancer drug	***
ombitasvir/paritaprevir /ritonavir	Hepatitis C direct acting antiviral	***
pethidine	Analgesic	XXX
phenobarbital	Anticonvulsant	XXX
phenytoin	Anticonvulsant	XXX
pimozide	Antipsychotic	XXX
prednisone	Systemic corticosteroid	***
propafenone	Antiarrhythmic	XXX
propoxyphene	Analgesic	XXX
quetiapine	Antipsychotic	***
quinidine	Antiarrhythmic	XXX
ranolazine	Antianginal	XXX

Drug	Drug Class	Interaction Code
rifabutin	Antimycobacterial	***
rifampin	Antimycobacterial	XXX
rivaroxaban	Anticoagulant	***
salmeterol	Long-acting beta-adrenoceptor agonist	***
sildenafil (Revatio®) when used for pulmonary arterial hypertension	PDE5 inhibitor	XXX
sirolimus	Immunosuppressant	***
sofosbuvir/velpatasvir/ voxilaprevir	Hepatitis C direct acting antiviral	***
St. John's Wort (hypericum perforatum)	Herbal product	XXX
tacrolimus	Immunosuppressant	***
trazodone	Antidepressant	***
triamcinolone	Systemic corticosteroid	***
triazolam	Sedative/hypnotic	XXX
venetoclax	Anticancer drug	***
vinblastine	Anticancer drug	***
vincristine	Anticancer drug	***
voriconazole	Antifungal	***
warfarin	Anticoagulant	***

Reference: University of Liverpool COVID-19 Drug Interactions: <https://www.covid19-druginteractions.org/checker>